Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

SECTION 1.2

Description of the concentration

Funds managed or advised by Intermediate Capital Group plc (“ICG”) intend to take – indirectly – joint control over AMEOS Gruppe AG (“AMEOS”), alongside current joint controller Dr. Axel Paeger (“Dr. Paeger”). ICG will take joint control by way of an acquisition of shares and other interests from funds doing business as the Carlyle Group, and funds managed by Quadriga Capital, both of whom will exit AMEOS as a result of the transaction.

• ICG: a UK-based investment firm, which is active in the structuring and provision of mezzanine finance, leveraged credit and minority and majority equity. ICG’s direct investment team is active in making minority and majority equity investments in companies across Europe, Asia Pacific and the US.

• Dr. Paeger: a German national, and founder and Chief Executive Officer of AMEOS.

• AMEOS: a Switzerland-based private operator of acute general hospitals, and acute psychiatric hospitals, as well as long-term elderly care and long-term mental care facilities in Germany, Austria and Switzerland.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.